

POLICY: Immunologicals – Xolair Utilization Management Medical Policy

- Xolair® (omalizumab subcutaneous injection – Genentech/Novartis)

EFFECTIVE DATE: 01/01/2021

LAST REVISION DATE: 05/22/2025

COVERAGE CRITERIA FOR: All Aspirus Medicare Plans

SUMMARY OF EVIDENCE

Xolair, an anti-immunoglobulin (Ig)E monoclonal antibody, is indicated for the following uses:¹

- **Asthma**, in patients ≥ 6 years of age with moderate to severe persistent disease who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids (ICSs). Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Limitations of Use: Xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. It is also not indicated for the treatment of other allergic conditions.
- **Chronic rhinosinusitis with nasal polyps** (CRSwNP), as add-on maintenance treatment in patients ≥ 18 years of age with an inadequate response to nasal corticosteroids.
- **Chronic spontaneous urticaria**, in patients ≥ 12 years of age who remain symptomatic despite H1 antihistamine treatment. Limitation of Use: Xolair is not indicated for the treatment of other forms of urticaria.
- **IgE-mediated food allergy**, in patients ≥ 1 year of age, for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. Xolair is to be used in conjunction with food allergen avoidance. Limitation of Use: Xolair is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

Dosing of Xolair for the treatment of asthma or nasal polyps is based on body weight and the serum total IgE level measured before the start of treatment.¹ Dosing for these indications is only provided for patients with a pretreatment serum IgE level ≥ 30 IU/mL. Dosing of Xolair in patients with chronic idiopathic urticaria is not dependent on serum IgE level or body weight.

Clinical Efficacy

Timing of efficacy assessments varied by indication across the numerous pivotal studies in which Xolair demonstrated benefit. In the majority of the asthma trials, efficacy with Xolair was assessed as early as 16 weeks.¹⁻¹¹ In chronic spontaneous urticaria, one of the studies included a 12-week double-blind treatment period, while the other was longer with 24 weeks of double-blind treatment.^{12,13} Across both studies evaluating Xolair in nasal polyps, efficacy was evaluated at Week 24.¹⁴ Patients continued treatment with intranasal corticosteroids throughout the study. In the

pivotal study of Xolair for food allergy, patients were required to have a positive skin prick test response to a food and to have a positive IgE test to food.¹⁵ Patients were provided with an epinephrine auto-injector throughout the study.

Guidelines

Asthma Guidelines

The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention (2024) proposes a step-wise approach to asthma treatment.¹⁶ Xolair is listed as an option for add-on therapy in patients ≥ 6 years of age with severe allergic asthma. Severe asthma is defined as asthma that is uncontrolled despite adherence to optimized high-dose ICS/long-acting beta₂-agonist (LABA) therapy or that worsens when high-dose treatment is decreased. Allergy-driven symptoms and childhood-onset asthma may predict a good asthma response to Xolair.

According to the European Respiratory Society/American Thoracic Society guidelines (2014; updated in 2020), severe asthma is defined as asthma which requires treatment with a high-dose ICS in addition to a second controller medication (and/or systemic corticosteroids) to prevent it from becoming uncontrolled, or asthma which remains uncontrolled despite this therapy.^{17,18} Uncontrolled asthma is defined as asthma that worsens upon tapering of high-dose ICS or systemic corticosteroids or asthma that meets one of the following four criteria:

- 1) Poor symptom control: Asthma Control Questionnaire consistently ≥ 1.5 or Asthma Control Test < 20 ;
- 2) Frequent severe exacerbations: two or more bursts of systemic corticosteroids in the previous year;
- 3) Serious exacerbations: at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year;
- 4) Airflow limitation: forced expiratory volume in 1 second (FEV₁) $< 80\%$ predicted after appropriate bronchodilator withholding.

Chronic Rhinosinusitis with Nasal Polyps Guidelines

The Joint Task Force on Practice Parameters (JTFPP) published a focused guideline update for the medical management of CRSwNP (2023), which updated recommendations regarding intranasal corticosteroids and biologic therapies.²⁰ Intranasal corticosteroids are recommended for the treatment of CRSwNP. Use of biologics (e.g., Xolair) are also recommended. However, in patients who derived a sufficient benefit from other therapies such as intranasal corticosteroids, surgery, or aspirin therapy after desensitization, biologics may not be preferred. Conversely, biologics may be preferred over other medical treatment options in patients who continue to have a high burden of disease despite receiving at least 4 weeks of treatment with an intranasal corticosteroid.

The diagnosis of CRSwNP was not addressed in this focused guideline update. Previous guidelines have noted that the presence of two or more signs and symptoms of chronic rhinosinusitis (e.g., rhinorrhea, postnasal drainage, anosmia, nasal congestion, facial pain, headache, fever, cough, and purulent discharge) that persist for an extended period of time makes the diagnosis of chronic rhinosinusitis likely.²¹⁻²⁴ However, this requires confirmation of sinonasal inflammation, which can

either be done via direct visualization or computed tomography (CT) scan. Oral corticosteroids and surgical intervention were not specifically addressed in this update. Prior guidelines recommend short courses of oral corticosteroid as needed and consideration of surgical removal as an adjunct to medical therapy in patients with CRSwNP that is not responsive or is poorly responsive to medical therapy.^{21,22,24}

Chronic Spontaneous Urticaria Guidelines

Guidelines for the definition, classification, diagnosis, and management of urticaria have been published by the European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/Asia Pacific Association of Allergy, Asthma and Clinical Immunology (2022).¹⁹ The American Academy of Dermatology was involved in the development of these guidelines and endorses their recommendations. Chronic spontaneous urticaria is defined as the appearance of wheals, angioedema, or both for > 6 weeks due to known or unknown causes. Signs and symptoms may be present daily/almost daily or have an intermittent recurrent course. Second generation H1-antihistamines taken regularly are the recommended first-line treatment for all types of urticaria following elimination of possible underlying causes. If standard doses do not eliminate urticaria signs and symptoms, the dose of the antihistamine should be increased up to 4-fold. If symptoms persist following 2 to 4 weeks of antihistamine therapy, the addition of Xolair may be considered. For patients with refractory chronic urticaria, the addition of Xolair may be considered. Short courses of rescue systemic corticosteroids are recommended for treatment of patients with acute exacerbations of chronic urticaria. However, guidelines recommend against the long-term use of systemic steroids.

Food Allergy Guidelines

Consensus-based guidance on the use and implementation of Xolair as food allergy treatment from the American Academy of Allergy, Asthma, and Immunology Adverse Reactions to Foods Committee (2025) note that Xolair is a potential treatment option which can be offered to patients with one or more IgE-mediated food allergies.²⁵ All candidates for Xolair therapy for food allergy should have a total IgE level that allows for Xolair dosing (i.e., > 30 to < 1,850 IU/mL). It is also recommended that patients have evidence of sensitization determined via either (or both) a positive food-specific skin prick test or measurement of a serum-specific IgE level to a food that would indicate a high likelihood of having an IgE-mediated reaction within the context of the patient's history. Both skin testing and specific IgE testing are not required as long as sensitization can be documented to one or more foods.

ANALYSIS OF EVIDENCE

The information provided in the summary of evidence is supported by labeled indications, CMS-approved compendia, published clinical literature, clinical practice guidelines, and/or applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs). Refer to the Sources of Information section of this policy for additional information.

POLICY STATEMENT

Prior authorization is recommended for medical benefit coverage of Xolair. Approval is recommended for those who meet the **Criteria** and **Dosing** the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. All approvals are provided for the durations noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), as well as in companion policy articles and other guidance applicable to the relevant service areas. These documents are cited in the Sources of Information section of this policy. In some cases, this guidance includes specific lists of HCPCS and ICD-10 codes to help inform the coverage determination process. The Articles that include specific lists for billing and coding purposes will be included in the Sources of Information section of this policy. However, to the extent that this policy cites such lists of HCPCS and ICD-10 codes, they should be used for reference purposes only. The presence of a specific HCPCS or ICD-10 code in a chart or companion article to an LCD is not by itself sufficient to approve coverage. Similarly, the absence of such a code does not necessarily mean that the applicable condition or diagnosis is excluded from coverage.

Note: Conditions for coverage outlined in this Medicare Advantage Medical Policy may be less restrictive than those found in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles. Examples of situations where this clinical policy may be less restrictive include, but are not limited to, coverage of additional indications supported by CMS-approved compendia and the exclusion from this policy of additional coverage criteria requirements outlined in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles.

Indications with a ^ below are referenced in both the corresponding Standard Medical Utilization Management Internal Policy AND applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs). Coverage criteria for these indications may be internally developed and/or referenced in applicable NCDs, LCDs, and/or LCAs. For these indications, internally developed coverage criteria is denoted throughout the policy in the following manner: 1) IC-L (internal criteria supported by the labeled indication), 2) IC-COMP (internal criteria supported by CMS-approved compendia), 3) IC-ISGP (internal criteria intended to interpret or supplement general provisions outlined in applicable NCDs, LCDs, and/or LCAs), or 4) IC-EC (internal criteria intended to expand coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs). For these indications, coverage criteria that is NOT denoted with one of the above indicators is referenced in applicable NCDs, LCDs, and/or LCAs. Additional information supporting the rationale for determination of internal coverage criteria can be found via the Sources of Information section.

Indications with a @ below are referenced in the corresponding Standard Medical Utilization Management Internal Policy, but are NOT directly referenced in applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs). Coverage criteria for these indications is internally developed. These indications and their respective

coverage criteria represent expanded coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs.

Indications with a # below are supported and referenced in applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs), but are NOT directly referenced in the corresponding Standard Medical Utilization Management Internal Policy. Coverage criteria for these indications is referenced in applicable NCDs, LCDs, and/or LCAs.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Xolair is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. Asthma. ^

Criteria. Approve Xolair for the duration noted if the patient meets one of the following conditions (A or B):

A) Initial Therapy. Approve for 4 months if the patient meets the following criteria (i, ii, iii, and iv):

- i. The patient is ≥ 6 years of age; ^{IC-L} AND
- ii. The patient has a baseline positive skin test or *in vitro* test (i.e., a blood test) for allergen-specific immunoglobulin E (IgE) for one or more perennial aeroallergens and/or for one or more seasonal aeroallergens; ^{IC-L, IC-EC} AND

Note: “Baseline” is defined as prior to receiving any Xolair or another monoclonal antibody therapy that may interfere with allergen testing (e.g., Dupixent and Tezspire). Examples of perennial aeroallergens are house dust mite, animal dander, cockroach, feathers, and mold spores. Examples of seasonal aeroallergens are grass, pollen, and weeds.

- iii. Patient has received at least 3 consecutive months of therapy with an inhaled corticosteroid; ^{IC-L, IC-ISGP} AND

Note: Use of a combination inhaler containing an inhaled corticosteroid would fulfill this requirement. Examples of inhaled corticosteroids include Aerospir, Alvesco, ArmonAir RespiClick, Arnuity Ellipta, Asmanex Twisthaler/HFA, Flovent Diskus/HFA, Pulmicort Flexhaler, Qvar/Qvar RediHaler, and budesonide suspension for inhalation (Pulmicort Respules, generics). Examples of combination inhalers containing an inhaled corticosteroid include Advair Diskus (generic Wixela Inhub; authorized generics), Advair HFA, AirDuo RespiClick (authorized generics), Breo Ellipta, Dulera, and Symbicort.

- iv. The patient has asthma that is uncontrolled or was uncontrolled at baseline as defined by ONE of the following (a, b, c, d, e, f, g, h, or i): ^{IC-L}

Note: “Baseline” is defined as prior to receiving Xolair or another monoclonal antibody therapy for asthma. Examples of monoclonal antibody therapies for asthma include Cinqair, Dupixent, Fasenra, Nucala, Tezspire, and Xolair.

- a. Daily symptoms or symptoms throughout the day; OR
 - b. Daily use of inhaled short-acting beta₂-agonist or use of inhaled short-acting beta 2-agonist several times per day; OR
 - c. Some limitation with normal activity or extremely limited normal activity; OR
 - d. The patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR
 - e. The patient experienced one or more asthma exacerbation requiring a hospitalization, an emergency department (ED) visit, or an urgent care visit in the previous year; ^{IC-EC} OR
 - f. Nighttime symptoms greater than 1 time a week but not nightly or nighttime symptoms often 7x/week; OR
 - g. Patient has a forced expiratory volume in 1 second (FEV₁) < 80% predicted; OR
 - h. Patient has an FEV₁/forced vital capacity (FVC) < 0.80 or the patient's FEV₁/forced vital capacity (FVC) is reduced by ≥ 5%; OR
 - i. The patient's asthma worsens upon tapering of oral corticosteroid therapy; ^{IC-EC} OR
- B) Patient is Currently Receiving Xolair.** Approve Xolair for 1 year if the patient meets the following criteria (i, ii, and iii):
- i. The patient has already received at least 4 months of therapy with Xolair; ^{IC-ISGP} AND
Note: A patient who has received < 4 months of therapy or who is restarting therapy with Xolair should be considered under criterion 1A (Asthma, Initial Therapy).
 - ii. Patient continues to receive therapy with one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler; ^{IC-ISGP} AND
 - iii. The patient has responded to therapy, as determined by the prescriber; ^{IC-ISGP} AND
Note: Examples of a response to Xolair therapy are decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department/urgent care, or medical clinic visits due to asthma; decreased reliever/rescue medication use; and improved lung function parameters.

Dosing. Approve up to a maximum dose of 375 mg administered subcutaneously (SC) not more frequently than once every 2 weeks.

**See Exhibit 1 for normal ranges of FEV1/FVC by age range*

2. Chronic Spontaneous Urticaria (Chronic Idiopathic Urticaria). [^]

Criteria. Approve Xolair for the duration noted if the patient meets one of the following conditions (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets the following criteria (i and ii):
- i. The patient is ≥ 12 years of age; ^{IC-L} AND

- ii. Patient has/had urticaria for > 6 weeks (prior to treatment with Xolair), with symptoms present > 3 days per week despite daily non-sedating H₁ antihistamine therapy with doses that have been titrated up to a maximum of four times the standard FDA-approved dose. ^{IC-L, IC-ISGP}

Note: Examples of non-sedating H₁ antihistamine therapy are cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine.

- B) Patient is Currently Receiving Xolair.** Approve Xolair for 1 year if the patient meets the following criteria (i and ii):

- i. The patient has already received at least 6 months of therapy with Xolair; ^{IC-ISGP} **AND**
Note: A patient who has received < 6 months of therapy or who is restarting therapy with Xolair should be considered under criterion 2A (Chronic Spontaneous Urticaria, Initial Therapy).
- ii. Patient has experienced a beneficial clinical response, defined by ONE of the following (a, b, or c): ^{IC-ISGP}
 - a) Decreased itch severity; ^{IC-ISGP} **OR**
 - b) Decreased number of hives; ^{IC-ISGP} **OR**
 - c) Decreased size of hives. ^{IC-ISGP}

Dosing. Approve the following dosing regimens (A or B):

- A) 150 mg administered subcutaneously (SC) once every 4 weeks; **OR**
- B) 300 mg administered subcutaneously (SC) once every 4 weeks.

3. Chronic Rhinosinusitis with Nasal Polyps. [^]

Criteria. Approve Xolair for the duration noted if the patient meets one of the following conditions (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets the following criteria (i, ii, iii and iv):

- i. Patient is ≥ 18 years of age; ^{IC-L} **AND**
- ii. Patient has chronic rhinosinusitis with nasal polyposis as evidenced by direct examination, endoscopy, or sinus computed tomography (CT) scan; ^{IC-ISGP} **AND**
- iii. Patient will receive therapy with an intranasal corticosteroid concomitantly with Xolair; ^{IC-L} **AND**
- iv. Patient meets ONE of the following (a, b or c):
 - a. Patient has had an inadequate response to an intranasal corticosteroid; ^{IC-L} **OR**
 - b. Patient has received at least one course of treatment with a systemic corticosteroid for 5 days or more within the previous 2 years; ^{IC-EC} **OR**
 - c. Patient has a contraindication to systemic corticosteroid therapy; ^{IC-EC} **OR**
 - d. Patient has had prior surgery for nasal polyps. ^{IC-EC}

- B) Patient is currently receiving Xolair.** Approve for 1 year if the patient meets the following criteria (i, ii and iii):

- i. Patient has already received at least 6 months of therapy with Xolair; ^{IC-ISGP} **AND**

Note: A patient who has received < 6 months of therapy or who is restarting therapy with Xolair should be considered under criterion 3A [Nasal Polyps, Initial Therapy]).

- ii. Patient continues to receive therapy with an intranasal corticosteroid; ^{IC-ISGP} AND
- iii. Patient has responded to Xolair therapy as determined by the prescriber. ^{IC-ISGP}

Note: Examples of a response to Xolair therapy are reduced nasal polyp size, improved nasal congestion, reduced sinus opacification, decreased sino-nasal symptoms, and/or improved sense of smell.

Dosing. Approve up to a maximum dose of 600 mg administered subcutaneously (SC) not more frequently than once every 2 weeks.

4. Immunoglobulin (Ig)E-Mediated Food Allergy. [^]

Criteria. Approve Xolair for 1 year if the patient meets ALL of the following (A, B and C):

- A) Patient is ≥ 1 year of age; ^{IC-L} AND
- B) Patient meets ONE of the following (i or ii):
 - i. Patient has a positive skin prick test response to one or more foods; ^{IC-ISGP} OR
 - ii. Patient has a positive *in vitro* test (i.e., a blood test) for IgE to one or more foods; ^{IC-ISGP} AND
- C) According the prescriber, Xolair will be used in conjunction with a food allergen-avoidant diet. ^{IC-L}

Dosing. Approve up to a maximum dose of 600 mg administered subcutaneously not more frequently than once every 2 weeks.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Xolair is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

SOURCES OF INFORMATION

1. Xolair® subcutaneous injection [prescribing information]. South San Francisco, CA and East Hanover, NJ: Genentech and Novartis; February 2024.
2. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol.* 2001;108(2):184-190.
3. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *J Allergy Clin Immunol.* 2003;111(2):278-284.
4. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. *Ann Allergy Asthma Immunol.* 2003;91:154-159.
5. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. *Chest.* 2004;125(4):1378-1386.
6. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J.* 2001;18:254-261.

7. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *Eur Respir J*. 2002;20:73-78.
8. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Respir J*. 2002;20:1088-1094.
9. Holgate S, Chuchalin A, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy*. 2004;34:632-638.
10. Kulus M, Hebert J, Garcia E, et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. *Curr Med Res Opin*. 2010;26:1285-1293.
11. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics*. 2001;108(2).
12. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol*. 2015;135:67-75.
13. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med*. 2013;368:924-935.
14. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis; 2 randomized phase 3 trials. *J Allergy Clin Immunol*. 2020;146(3):595-605.
15. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. *N Engl J Med*. 2024;390(10):889-899.
16. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2024. Available at: <http://www.ginasthma.org>. Accessed on: February 24, 2025.
17. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43:343-373.
18. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. *Eur Respir J*. 2020;55:1900588.
19. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy*. 2022;73:734-766.
20. Rank MA, Chu DK, Bognanni A, et al. Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol*. 2023;151(2):386-398.
21. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immunol*. 2014;347-385.
22. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidenced-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017;119(6):489-511.
23. Joint Task Force on Practice Parameters: American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol*. 2020;146:721-767.
24. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2S):S1-S39.
25. Anagnostou A, Bird JA, Chinthraja S, et al. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2025;155(1):62-69.
26. Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. *JAMA Pediatr*. 2019;174(1):29-37.
27. Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. *Int J Dermatol*. 2017;56(1):18-26.
28. Wang HH, Li YC, Huang YC, et al. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2016;138(6):1719-1722.
29. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol*. 2024;90(2):E43-E56.
30. Baccelli A, Kocwin M, Parazzini EM, et al. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. *J Asthma*. 2023;60(5):1050-1053.
31. Altman MC, Lenington J, Bronson S, et al. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol Pract*. 2017;5(4):1137-1139.
32. Han D, Lee JK. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. *Ann Allergy Asthma Immunol*. 2018;121(6):742-743.
33. Dedaj R, Unsel L. Case study: a combination of mepolizumab and omalizumab injections for severe asthma. *J Asthma*. 2019;56(5):473-474.
34. Matsumoto T, Sakurai Y, Tashima N, et al. Dual biologics for severe asthma and atopic dermatitis: synopsis of two cases and literature review. *Respirol Case Rep*. 2023;12(1):e01266.

35. Sezgin ME, Colak M, Caglayan O, et al. Efficacy and mepolizumab and omalizumab combination therapy in uncontrolled asthma. *J Asthma*. 2024;61(2):173-175.
36. Gisondi P, Maurelli M, Costanzo A, et al. The combination of dupilumab with other monoclonal antibodies. *Dermatol Ther (Heidelb)*. 2023;13(1):7-12.
37. Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. *Am J Gastroenterol*. 2025;120(1):31-59.
38. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy [letter]. *J Allergy Clin Immunol*. 2004;113(2):360-361.
39. Centers for Medicare and Medicaid Services, National Government Services, Inc, Local Coverage Article: Billing and Coding: Omalizumab (e.g., Xolair®) – Related to LCD L33394 (A52448) [original date 10/01/2015; revision effective date 2/16/24]. Accessed on May 22, 2025.
40. Centers for Medicare and Medicaid Services, National Government Services, Inc, Local Coverage Determination (LCD): Drugs and Biologicals, Coverage of, for Label and Off-Label Uses (L33394) [original date 10/01/2015; revision effective date 8/1/24]. Accessed on May 22, 2025.

EXHIBIT 1

Normal ranges by age for FEV₁/FVC are as follows (National Heart, Lung, and Blood Institute [NHLBI]):

- 8-19 years of age – 85%;
- 20-39 years of age – 80%;
- 40-59 years of age – 75%;
- 60-80 years of age – 70%

HISTORY

Type of Revision	Summary of Changes	Date
Policy created	New Medicare Advantage Medical Policy	07/11/2018
Policy revision	Reviewed and revised original policy created 07/11/2018 in accordance with Local Coverage Article A52448.	02/20/2019
Policy revision	Completion of 2019 monthly monitoring process in accordance with Local Coverage Determination L33394, Local Coverage Article A52448.	12/11/2019
Policy revision	Non-clinical update to policy to add the statement “This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), as well as in companion policy articles and other guidance applicable to the relevant service areas. These documents are cited in the References section of this policy. In some cases, this guidance includes specific lists of HCPCS and ICD-10 codes to help inform the coverage determination process. The Articles that include specific lists for billing and coding purposes will be included in the Reference section of this policy. However, to the extent that this policy cites such lists of HCPCS and ICD-10 codes, they should be used for reference purposes only. The presence of a specific HCPCS or ICD-10 code in a chart or companion article to an LCD is not by itself sufficient to approve coverage. Similarly, the absence of such a code does <u>not</u> necessarily mean that the applicable condition or diagnosis is excluded from coverage.”	1/30/2020
Policy revision	Reviewed and revised original policy created 07/11/2018 in accordance with Local Coverage Determination L33394, Local Coverage Article A52448.	02/12/2020

Policy revision	<ul style="list-style-type: none"> Asthma – changed wording for the indication, simplified to asthma. Also changed “moderate to severe requirement” to “uncontrolled or was uncontrolled prior to receiving any Xolair or anti-IL-4/13 therapy (Dupixent) therapy” and added additional options to meet that criteria, Added criteria requiring patient to continue therapy with an ICS or ICS-containing product for continuation of coverage. All indications – removed requirement that Xolair be administered by a physician or incident to a physician’s service in office/clinic setting. Removed Allergic rhinitis as a covered condition Removed self-administration of Xolair and acute bronchospasm or status asthmaticus from conditions not recommended for approval 	3/26/2020
Policy revision	New indication - Nasal Polyps: criteria for this indication – for initial therapy includes an age requirement, current intranasal corticosteroid therapy, previous systemic therapy (or contraindication) or surgery for nasal polyps or previous inadequate response to an intranasal corticosteroid. For continuation therapy, requires patient has already received at least 6 months of therapy with Xolair, patient continues to receive therapy with an intranasal corticosteroid, and that pt has had a response to therapy.	01/06/2021
Policy revision	Nasal Polyps: Added criteria requiring patient have chronic rhinosinusitis with nasal polyposis as evidenced by direct examination, endoscopy, or sinus computed tomography (CT) scan. Changed criteria requiring patient be currently receiving a nasal corticosteroid to Patient will receive therapy with an intranasal corticosteroid concomitantly with Xolair. Clarified the systemic corticosteroid criteria to require that the patient has received at least one course of systemic corticosteroids for at least 5 days in the previous 2 years.	07/20/2021
Policy revision	Asthma: Notes were also updated to include Xolair, Cinqair, Fasenra, Nucala, and Tezspire as examples of monoclonal antibody therapies for asthma. Criteria requiring the patient to have experienced one or more asthma exacerbation(s) requiring a hospitalization or an emergency department visit in the previous year, were updated to include an urgent care visit as well.	08/03/2022
Policy review	No criteria changes	03/22/2023
Policy revision	Chronic Rhinosinusitis with Nasal Polyps: Approval condition updated from “Nasal Polyps” to “Chronic Rhinosinusitis with Nasal Polyps”. IgE-Mediated Food Allergy: New approval criteria for this indication were added.	04/24/2024
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/16/2024
Policy revision	No criteria changes. Formatting and notation updates.	03/03/2025
Policy revision	Immunoglobulin (IgE)-Mediated Food Allergy: Criteria were updated to require the patient to have either a positive skin prick test response OR a positive <i>in vitro</i> test (i.e., a blood test) for IgE to one or more foods. Previously, criteria required the patient to have both a positive skin prick test response and a positive <i>in vitro</i> test (i.e., a blood test) for IgE to one or more foods.	04/08/2025
Policy revision	Chronic Spontaneous Urticaria (Chronic Idiopathic Urticaria): Approval condition was updated to “Chronic Spontaneous Urticaria (Chronic Idiopathic Urticaria)”. Previously, this approval condition was listed as “Chronic Idiopathic Urticaria (Chronic Spontaneous Urticaria). The approval duration for this condition was changed from 4 months to 6 months. Criteria for a patient currently receiving Xolair was updated to apply to a patient who has already received at least 6 months of therapy with Xolair. Previously, these criteria applied to a patient who had received at least 4 months of therapy with Xolair. Criteria for a patient	05/22/2025

	currently receiving Xolair was also updated to require that the patient has experienced a beneficial clinical response, defined as either decreased itch severity, decreased number of hives, or decreased size of hives. Previously, these criteria required the patient to have responded to therapy as determined by the prescriber.	
--	---	--